세계의 파킨슨병 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 작용기전별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Parkinson´s Disease Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Mechanism of Action, By Distribution Channel, By Region & Competition, 2020-2030F
상품코드:1698052
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
파킨슨병 치료제 세계 시장 규모는 2024년 55억 5,000만 달러로 평가되었고, 2030년까지 7.45%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 괄목할 만한 성장을 이룰 것으로 예상됩니다.
파킨슨병은 주로 운동 조절에 영향을 미치는 중추신경계의 만성적이고 진행성 신경 퇴행성 질환입니다. 다양한 운동 증상을 특징으로 하며, 비운동 증상을 동반하기도 합니다. 안정시 떨림은 파킨슨병의 특징적인 증상입니다. 이러한 비자발적 떨림은 보통 팔다리가 쉬고 있을 때 발생하며, 종종 손가락의 리드미컬한 '알약 굴리기' 동작을 동반합니다. 파킨슨병에서는 근육의 경직과 수동적 운동에 대한 저항 증가가 흔히 나타납니다. 이러한 경직은 다양한 근육 그룹에 영향을 미쳐 신체적 불편함을 유발합니다. 파킨슨병이 진행되면 균형 장애와 낙상 경향이 나타날 수 있습니다. 직립 자세를 유지하는 것이 어려워지고 원인을 알 수 없는 낙상을 경험할 수 있습니다. 파킨슨병은 기분 변화(우울, 불안 등), 수면장애, 인지 장애, 자율신경 기능 장애(변비, 기립성 저혈압 등), 감각 변화 등 다양한 비운동 증상을 동반할 수 있습니다.
Global Parkinson's Disease Drugs Market was valued at USD 5.55 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.45% through 2030. Parkinson's disease is a chronic and progressive neurodegenerative disorder of the central nervous system that primarily affects movement control. It is characterized by a range of motor symptoms and can also involve non-motor symptoms. Resting tremors are a hallmark symptom of Parkinson's disease. These involuntary shaking movements typically occur when the affected limb is at rest and often involve a rhythmic "pill-rolling" motion of the fingers. Muscle stiffness and increased resistance to passive movement are common in Parkinson's disease. This rigidity can affect various muscle groups and lead to a sense of physical discomfort. Balance problems and a tendency to fall can develop as Parkinson's disease progresses. Individuals may have difficulty maintaining an upright posture and may experience unexplained falls. Parkinson's disease can involve a range of non-motor symptoms, including mood changes (such as depression and anxiety), sleep disturbances, cognitive impairment, autonomic dysfunction (such as constipation and orthostatic hypotension), and sensory changes.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 5.55 Billion
Market Size 2030
USD 8.56 Billion
CAGR 2025-2030
7.45%
Fastest Growing Segment
MAO-B inhibitors
Largest Market
North America
Key Market Drivers
Advancements in Technology
Implantable or wearable devices that deliver medication continuously or on-demand have been developed. These devices can provide a more stable and consistent drug delivery, reducing motor fluctuations and the need for frequent dosing. Advances in drug formulation techniques have led to the development of extended-release and controlled-release formulations. These formulations can help maintain therapeutic drug levels in the body over an extended period, reducing the frequency of medication administration. Inhalable levodopa formulations have been developed to provide rapid relief of motor symptoms. These inhalers can be particularly beneficial for patients who experience sudden "off" periods. Research is ongoing to identify and develop neuroprotective drugs that may slow the progression of Parkinson's disease. These drugs aim to protect and preserve dopamine-producing neurons in the brain. Advances in genetic testing and biomarker identification are enabling more personalized treatment approaches. Tailoring medication regimens to an individual's genetic profile and disease stage can optimize treatment outcomes. Prodrugs are inactive compounds that convert into active drugs within the body. Some prodrugs have been designed to improve the delivery of levodopa, the primary treatment for PD, and reduce side effects.
Key Market Challenges
Side Effects and Tolerability
Some Parkinson's disease drugs, particularly levodopa, can lead to motor fluctuations, including "on-off" periods, dyskinesias (involuntary movements), and wearing-off phenomena. These fluctuations can be disruptive and challenging to manage. Many Parkinson's drugs can cause gastrointestinal side effects such as nausea, vomiting, and constipation. These side effects can affect medication absorption and patient compliance. Dopaminergic medications, including dopamine agonists, can lead to psychiatric side effects like hallucinations, impulse control disorders, and mood disturbances. These can have a significant impact on a patient's mental well-being. Some medications may exacerbate cognitive impairment in Parkinson's disease patients, particularly in advanced stages of the disease. This can include impairments in memory, attention, and executive function. Parkinson's disease drugs can lower blood pressure, leading to orthostatic hypotension, a condition where blood pressure drops significantly upon standing. This can result in dizziness, falls, and fainting. Medications can affect sleep patterns, leading to insomnia or excessive daytime sleepiness. Sleep disturbances can further worsen the quality of life for patients. Dopamine agonists can sometimes cause impulsive behaviors, including gambling and hypersexuality. These behaviors can strain relationships and have financial and social consequences. Patients with Parkinson's disease often take multiple medications to manage their symptoms and comorbid conditions. Drug interactions can occur, potentially leading to adverse effects or reduced drug efficacy.
Key Market Trends
Patient-Centric Approaches
Recognizing that Parkinson's disease can manifest differently in each patient, healthcare providers are increasingly tailoring treatment plans to the specific needs and characteristics of individuals. Genetic testing and other biomarker assessments may be used to determine the most appropriate medications and dosages. Patient-centric care emphasizes the importance of involving patients in their own care decisions. It considers their preferences, values, and goals when developing treatment plans. This approach fosters a collaborative relationship between patients and healthcare providers. Shared decision-making is a fundamental aspect of patient-centric care. It involves a two-way exchange of information and decision-making between patients and healthcare providers to determine the most suitable treatment options based on the patient's preferences and circumstances. Educating patients about their condition, treatment options, and self-management strategies is crucial. Empowering patients with knowledge enable them to actively participate in their care and make informed decisions. A patient-centric approach often involves a multidisciplinary care team, including neurologists, physical therapists, occupational therapists, speech therapists, and mental health professionals. This team collaborates to address the diverse needs of Parkinson's patients.
Key Market Players
Amneal Pharmaceuticals LLC
AbbVie Inc.
Boehringer Ingelheim International GmbH
GSK plc
Teva Pharmaceuticals Industries Ltd
Pfizer Inc.
Novartis AG
F. Hoffmann-La Roche Ltd
Kissei Pharmaceutical Co., Ltd.
AstraZeneca Plc
Prevail Therapeutics (Eli Lilly and Company)
Newron Pharmaceuticals SPA
Report Scope:
In this report, the Global Parkinson's Disease Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Parkinson's Disease Drugs Market, By Mechanism of Action:
Dopamine Agonists
Anticholinergic
MAO-B Inhibitors
Amantadine
Carbidopa-levodopa
COMT Inhibitors
Other Mechanisms of Action
Parkinson's Disease Drugs Market, By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Others
Global Parkinson's Disease Drugs Market, By region:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Parkinson's Disease Drugs Market.
Available Customizations:
Global Parkinson's Disease Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Parkinson's Disease Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action)
5.2.2. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. Asia Pacific Parkinson's Disease Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Mechanism of Action
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Parkinson's Disease Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Mechanism of Action
6.3.1.2.2. By Distribution Channel
6.3.2. India Parkinson's Disease Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Mechanism of Action
6.3.2.2.2. By Distribution Channel
6.3.3. Australia Parkinson's Disease Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Mechanism of Action
6.3.3.2.2. By Distribution Channel
6.3.4. Japan Parkinson's Disease Drugs Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Mechanism of Action
6.3.4.2.2. By Distribution Channel
6.3.5. South Korea Parkinson's Disease Drugs Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Mechanism of Action
6.3.5.2.2. By Distribution Channel
7. Europe Parkinson's Disease Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Mechanism of Action
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Parkinson's Disease Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Mechanism of Action
7.3.1.2.2. By Distribution Channel
7.3.2. Germany Parkinson's Disease Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Mechanism of Action
7.3.2.2.2. By Distribution Channel
7.3.3. Spain Parkinson's Disease Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Mechanism of Action
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Parkinson's Disease Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Mechanism of Action
7.3.4.2.2. By Distribution Channel
7.3.5. United Kingdom Parkinson's Disease Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Mechanism of Action
7.3.5.2.2. By Distribution Channel
8. North America Parkinson's Disease Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Mechanism of Action
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Parkinson's Disease Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Mechanism of Action
8.3.1.2.2. By Distribution Channel
8.3.2. Mexico Parkinson's Disease Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Mechanism of Action
8.3.2.2.2. By Distribution Channel
8.3.3. Canada Parkinson's Disease Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Mechanism of Action
8.3.3.2.2. By Distribution Channel
9. South America Parkinson's Disease Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Mechanism of Action
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Parkinson's Disease Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Mechanism of Action
9.3.1.2.2. By Distribution Channel
9.3.2. Argentina Parkinson's Disease Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Mechanism of Action
9.3.2.2.2. By Distribution Channel
9.3.3. Colombia Parkinson's Disease Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Mechanism of Action
9.3.3.2.2. By Distribution Channel
10. Middle East and Africa Parkinson's Disease Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Mechanism of Action
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Parkinson's Disease Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Mechanism of Action
10.3.1.2.2. By Distribution Channel
10.3.2. Saudi Arabia Parkinson's Disease Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Mechanism of Action
10.3.2.2.2. By Distribution Channel
10.3.3. UAE Parkinson's Disease Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Mechanism of Action
10.3.3.2.2. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Parkinson's Disease Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Amneal Pharmaceuticals LLC
16.1.1. Business Overview
16.1.2. Product & Service Offerings
16.1.3. Recent Developments
16.1.4. Financials (If Listed)
16.1.5. Key Personnel
16.1.6. SWOT Analysis
16.2. AbbVie Inc.
16.3. Boehringer Ingelheim International GmbH
16.4. GSK plc
16.5. Teva Pharmaceuticals Industries Ltd
16.6. Pfizer Inc.
16.7. Novartis AG
16.8. F. Hoffmann-La Roche Ltd
16.9. Kissei Pharmaceutical Co., Ltd.
16.10. AstraZeneca Plc
16.11. Prevail Therapeutics (Eli Lilly and Company)
